tceanc2 Antibody

What is TCEANC2 and why is it studied in molecular biology?

TCEANC2 (Transcription Elongation Factor A N-terminal and Central domain-containing protein 2) is a 208 amino acid nuclear protein that exists in two alternatively spliced isoforms . The gene encoding TCEANC2 maps to human chromosome 1, specifically at position 1p32.3, which is significant as chromosome 1 is the largest human chromosome containing approximately 3,000 genes and representing about 8% of the human genome . TCEANC2 is studied primarily for its potential role in transcription elongation processes, which are fundamental to gene expression regulation. Understanding TCEANC2 function contributes to our knowledge of basic transcriptional mechanisms and may provide insights into disease states where transcriptional regulation is disrupted. The protein's association with the transcription elongation factor A family suggests its involvement in RNA polymerase II-mediated transcription, making it relevant to studies of gene expression control .

What types of TCEANC2 antibodies are available for research applications?

Several types of TCEANC2 antibodies are available for research applications, varying in host species, clonality, and target epitopes. Polyclonal antibodies raised in rabbits targeting the N-terminal region (amino acids 1-208) are commonly used for ELISA and immunohistochemistry applications . Goat polyclonal antibodies directed against the C-terminus of human TCEANC2 are available for Western blotting, immunofluorescence, and ELISA techniques . Mouse-derived polyclonal antibodies are also available for certain applications . In terms of conjugates, researchers can utilize unconjugated antibodies or those conjugated with various tags including HRP (horseradish peroxidase), FITC (fluorescein isothiocyanate), or biotin, depending on the specific detection method required . The choice between these antibody types depends on the experimental design, detection method, and specific research question being addressed. Different epitope targets (N-terminal vs. C-terminal) may also yield different results depending on protein conformation and accessibility in experimental conditions .

Which species reactivity should be considered when selecting TCEANC2 antibodies?

When selecting TCEANC2 antibodies, species reactivity is a critical consideration that directly impacts experimental validity. Available antibodies show varying cross-reactivity profiles across species. Some TCEANC2 antibodies are specifically reactive only with human TCEANC2 samples, limiting their use to human cell lines, tissues, or recombinant proteins . Other antibodies demonstrate broader cross-reactivity, recognizing TCEANC2 from multiple species including human, rat, and mouse samples . Some antibodies extend reactivity further to include horse, cow, and other mammalian species . This cross-reactivity information is essential when designing experiments using model organisms. Researchers working with rodent models should specifically select antibodies validated for rat/mouse reactivity, while those working with human samples or cell lines must ensure human reactivity. When comparing results across species, selecting antibodies with confirmed multi-species reactivity ensures consistent epitope recognition and reduces methodology-based variations in results .

How should TCEANC2 antibodies be optimized for Western blotting applications?

For optimal Western blotting results with TCEANC2 antibodies, several critical parameters require careful optimization. Begin with sample preparation by using appropriate lysis buffers containing protease inhibitors to prevent TCEANC2 degradation, which is particularly important for nuclear proteins . For gel electrophoresis, use 10-12% SDS-PAGE gels to effectively resolve the 30 kDa TCEANC2 protein . During transfer, nitrocellulose membranes often provide better results than PVDF for this protein. For primary antibody incubation, start with a dilution range of 1:100-1:1000 for rabbit polyclonal antibodies targeting TCEANC2, with overnight incubation at 4°C generally yielding optimal signal-to-noise ratios . When selecting positive controls, human fetal heart tissue extracts or HeLa whole cell lysates are recommended as validated controls for TCEANC2 detection . For secondary antibody selection, use species-appropriate conjugates such as donkey anti-goat IgG-HRP for goat primary antibodies . During optimization, run parallel blots with different blocking agents (5% BSA versus 5% non-fat milk) as TCEANC2 detection can be sensitive to blocking conditions. For signal development, extended exposure times may be necessary as TCEANC2 expression can be relatively low in some cell types .

What are the recommended protocols for immunohistochemistry using TCEANC2 antibodies?

For successful immunohistochemistry (IHC) with TCEANC2 antibodies, tissue preparation and antigen retrieval are crucial initial steps. Begin with proper fixation using 10% neutral buffered formalin, followed by paraffin embedding using standard protocols . For antigen retrieval, heat-induced epitope retrieval using citrate buffer (pH 6.0) has shown superior results for TCEANC2 detection, with pressure cooking for 15-20 minutes being particularly effective . When blocking, use a combination of serum (from the species of the secondary antibody) and 1-3% BSA to minimize background staining. For primary antibody incubation, TCEANC2 antibodies typically perform optimally at dilutions between 1:50-1:200, with overnight incubation at 4°C enhancing specific binding . For detection systems, polymer-based detection methods generally provide better sensitivity than avidin-biotin systems for TCEANC2 visualization. Nuclear counterstaining with hematoxylin should be kept brief (1-2 minutes) to avoid masking the specific nuclear localization of TCEANC2. When interpreting results, note that TCEANC2 expression is predominantly nuclear, and cytoplasmic staining may indicate non-specific binding or alternative splice variants . Including both positive controls (tissues known to express TCEANC2) and negative controls (primary antibody omission) is essential for validating staining specificity .

What considerations are important for immunofluorescence applications of TCEANC2 antibodies?

When performing immunofluorescence (IF) with TCEANC2 antibodies, several technical considerations significantly impact results. For cell preparation, fixation with 4% paraformaldehyde for 15-20 minutes at room temperature preserves TCEANC2 epitopes better than methanol fixation, which can disrupt nuclear protein epitopes . Permeabilization requires careful optimization as TCEANC2 is a nuclear protein; use 0.2-0.5% Triton X-100 for 10 minutes, as excessive permeabilization can lead to epitope loss while insufficient permeabilization prevents antibody access to nuclear antigens . For blocking, 5-10% normal serum from the secondary antibody host species supplemented with 1% BSA effectively reduces background. Primary antibody incubation should begin at a dilution of 1:50 and be titrated as needed, with overnight incubation at 4°C typically yielding optimal results . For co-localization studies, TCEANC2 antibodies can be paired with other nuclear markers such as DAPI and antibodies against transcription factors or nuclear matrix proteins. When imaging, use confocal microscopy to precisely visualize the nuclear localization pattern of TCEANC2, checking for expected punctate distribution consistent with transcription factor localization . For quantitative IF applications, establish consistent exposure settings and implement appropriate controls to ensure reliable inter-experimental comparisons of TCEANC2 expression levels .

How can researchers validate TCEANC2 antibody specificity for critical experiments?

Validating TCEANC2 antibody specificity is essential for generating reliable research data. For comprehensive validation, implement a multi-approach strategy beginning with knockout/knockdown controls. Use TCEANC2 siRNA (available catalog numbers sc-88814 for human and sc-108618 for mouse) or shRNA plasmids to create knockdown cell lines, which should show diminished signal with a specific antibody . For peptide competition assays, pre-incubate the TCEANC2 antibody with its specific immunizing peptide (such as sc-240117 P) at 5-10 fold molar excess before applying to samples; specific signals should be significantly reduced or eliminated . When performing Western blot validation, look for a single predominant band at the expected molecular weight of 30 kDa; multiple bands may indicate isoforms, degradation products, or non-specific binding . For orthogonal validation, compare results from antibodies targeting different epitopes of TCEANC2 (N-terminal versus C-terminal) across multiple applications; concordant results strengthen validity . In cross-application validation, consistent localization patterns across immunohistochemistry, immunofluorescence, and subcellular fractionation with Western blotting provide strong evidence for specificity. For mass spectrometry validation, immunoprecipitate TCEANC2 using the antibody and confirm target identity by mass spectrometry to definitively establish that the antibody captures the intended protein .

What are the key considerations for TCEANC2 co-immunoprecipitation experiments?

When designing co-immunoprecipitation (co-IP) experiments to investigate TCEANC2 protein-protein interactions, several methodological considerations are critical. For cell lysis, use gentle non-ionic detergents such as 0.5% NP-40 or 1% Triton X-100 in buffers containing 150 mM NaCl to preserve protein-protein interactions while effectively solubilizing nuclear proteins . Pre-clearing lysates with protein G beads for 1 hour at 4°C significantly reduces non-specific binding. For antibody selection, polyclonal antibodies typically perform better than monoclonal antibodies in co-IP applications due to their recognition of multiple epitopes; both N-terminal and C-terminal targeting antibodies should be tested as epitope accessibility can impact precipitation efficiency . For optimal antibody binding, use 2-5 μg of antibody per mg of protein lysate and incubate overnight at 4°C with gentle rotation. When selecting appropriate controls, include IgG from the same species as the primary antibody as a negative control, and when possible, include lysate from cells with TCEANC2 knockdown as an additional specificity control . For washing conditions, optimize stringency carefully; typically, 3-5 washes with decreasing salt concentrations (from 300 mM to 150 mM NaCl) balance removal of non-specific interactions while preserving genuine TCEANC2 complexes. For elution, non-denaturing conditions using competing peptides may better preserve complex integrity for downstream functional assays compared to boiling in SDS-PAGE sample buffer .

How does TCEANC2 alternative splicing affect antibody selection and experimental design?

TCEANC2 exists in at least two alternatively spliced isoforms, which creates significant implications for antibody selection and experimental design . For comprehensive isoform detection, select antibodies targeting conserved epitopes present in all known TCEANC2 isoforms; antibodies targeting the central domain are typically more likely to recognize multiple variants than those targeting potentially spliced terminal regions . Researchers should carefully review the immunogen sequence used for antibody production and compare it to known splice variant sequences to predict which isoforms will be detected. For isoform-specific detection, when available, select antibodies raised against unique junction peptides or sequences specific to particular splice variants, though these are currently limited for TCEANC2 . In experimental design, consider using RT-PCR with isoform-specific primers alongside immunodetection to correlate protein observations with transcript variants. When analyzing Western blot results, be aware that different TCEANC2 isoforms may appear as multiple bands with subtle molecular weight differences; careful molecular weight ladder calibration is essential for accurate isoform identification . For functional studies, consider that different isoforms may localize to different subcellular compartments or interact with distinct protein partners, necessitating careful compartment-specific analyses. When reporting research findings, explicitly state which TCEANC2 isoforms are likely being detected based on the antibody specifications to avoid confusion in the literature .

What are common challenges in TCEANC2 antibody applications and how can they be addressed?

Researchers frequently encounter several challenges when working with TCEANC2 antibodies across various applications. One common issue is high background signal in immunostaining, which can be addressed by increasing blocking stringency (using 5% BSA with 5% normal serum), extending blocking time to 2 hours, and implementing additional washing steps with 0.1% Tween-20 . For weak or absent TCEANC2 signal, optimize antigen retrieval for IHC by testing multiple methods (heat-induced versus enzymatic), adjust primary antibody concentration upward (try 1:50 dilution if 1:200 shows weak signal), or extend incubation times to overnight at 4°C . Non-specific bands in Western blotting can be reduced by increasing washing stringency, using freshly prepared blocking buffers, and implementing gradient gel systems that provide better separation around the 30 kDa range where TCEANC2 is detected . For inconsistent TCEANC2 immunoprecipitation results, pre-clearing lysates more thoroughly, increasing antibody amount (up to 5 μg), and extending incubation times can significantly improve results . When encountering discrepancies between antibody lots, perform side-by-side validation of new lots against previous lots before replacing them in established protocols. If experiencing difficulty detecting nuclear localization of TCEANC2, optimize permeabilization conditions specifically for nuclear proteins by testing increased concentrations of Triton X-100 (up to 0.5%) or consider adding a short (5 minute) methanol permeabilization step at -20°C .

How can researchers optimize antibody dilutions for different TCEANC2 detection methods?

Determining optimal antibody dilutions for TCEANC2 detection requires systematic titration across applications to balance signal strength and specificity. For Western blotting, begin with the manufacturer's recommended range (typically 1:200-1:1000 for most TCEANC2 antibodies) and prepare a dilution series spanning this range . Test these dilutions on identical protein samples with appropriate positive controls (HeLa cell lysates or human fetal heart tissue extracts), evaluating the signal-to-noise ratio and band specificity at each concentration . For immunohistochemistry, a more concentrated antibody preparation is typically required; start with dilutions between 1:50-1:200 and evaluate staining intensity, specificity, and background across this range on known positive control tissues . For immunofluorescence applications, begin titration at a dilution of 1:50 and extend the series to 1:500, assessing nuclear localization pattern clarity and background fluorescence . When optimizing ELISA applications with TCEANC2 antibodies, create a broader dilution series (1:30-1:3000) and generate a standard curve to determine the linear detection range for your specific sample type . For each application, perform parallel experiments with negative controls (isotype-matched irrelevant antibodies or secondary-only controls) to distinguish specific signal from background at each dilution. Document optimization results thoroughly, including incubation conditions (time, temperature) alongside dilution factors, as these parameters interact to determine final signal quality .

What factors affect the reproducibility of TCEANC2 antibody-based experiments?

Multiple factors can significantly impact the reproducibility of experiments utilizing TCEANC2 antibodies. Antibody lot-to-lot variation is a primary concern; manufacturers may use different immunogen preparations or purification protocols between production batches, leading to altered epitope recognition profiles . To mitigate this, maintain detailed records of lot numbers, request certificate of analysis data from suppliers, and validate new lots against previous ones before implementing them in critical experiments. Sample preparation consistency dramatically affects results; standardize cell lysis procedures, protein extraction methods, and storage conditions to minimize experiment-to-experiment variation . Protocol timing variations can alter results; standardize incubation times for primary and secondary antibodies, as well as development times for visualization reagents. Environmental factors such as temperature fluctuations during incubation steps can affect antibody binding kinetics; use temperature-controlled environments when possible . Detection system variations (different microscopes, imaging settings, or ECL reagents) can create apparent differences in results that are methodology-based rather than biological; maintain consistent detection parameters across experiments . Buffer composition changes, even minor ones, can affect antibody performance; prepare buffers in large batches and aliquot to ensure consistency. Cell culture conditions, including passage number, confluency at harvest, and serum batch, can alter TCEANC2 expression levels; standardize these variables across experimental replicates .

How can TCEANC2 antibodies be utilized in ChIP-seq experiments to study transcriptional regulation?

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) using TCEANC2 antibodies can provide valuable insights into the protein's role in transcriptional regulation. For optimal ChIP-seq results, antibody selection is critical; polyclonal antibodies targeting the N-terminal domain (amino acids 1-208) are generally preferred due to their recognition of multiple epitopes, which increases chances of binding to formaldehyde-fixed chromatin complexes . Prior to full-scale experiments, perform antibody validation specifically for ChIP applications using small-scale ChIP-qPCR on candidate regions, as antibodies that perform well in other applications may not function effectively in ChIP contexts . For crosslinking optimization, test both standard formaldehyde fixation (1% for 10 minutes) and dual crosslinking with additional protein-protein crosslinkers such as disuccinimidyl glutarate (DSG) to better preserve TCEANC2 interactions with chromatin . Sonication conditions require careful optimization for TCEANC2 ChIP-seq; start with moderate conditions (20-30 cycles of 30 seconds on/30 seconds off at medium power) and assess chromatin fragmentation to achieve fragments averaging 200-500 bp. Include appropriate controls in experimental design: input chromatin, IgG control, and ideally a TCEANC2 knockdown condition as a negative control . For bioinformatic analysis, compare TCEANC2 binding sites with known transcription elongation-associated marks such as phosphorylated RNA Polymerase II and H3K36me3 to contextualize its role in transcriptional regulation .

What approaches are recommended for studying TCEANC2 post-translational modifications?

Investigating post-translational modifications (PTMs) of TCEANC2 requires specialized antibody-based approaches and complementary techniques. To detect phosphorylation states, researchers should first enrich TCEANC2 through immunoprecipitation using general TCEANC2 antibodies, followed by Western blotting with phospho-specific antibodies if available . Alternatively, use phospho-enrichment techniques such as IMAC (Immobilized Metal Affinity Chromatography) or titanium dioxide chromatography prior to mass spectrometry analysis. For site-specific PTM mapping, immunoprecipitate TCEANC2 from cells treated with or without relevant signaling pathway activators/inhibitors, and analyze by mass spectrometry with specific attention to modification-specific mass shifts . To study ubiquitination and SUMOylation, perform immunoprecipitation under denaturing conditions (1% SDS lysis followed by dilution) to disrupt non-covalent interactions while preserving these covalent modifications, then probe with anti-ubiquitin or anti-SUMO antibodies . For temporal dynamics of TCEANC2 modifications, implement pulse-chase experimental designs combined with immunoprecipitation at different timepoints following cellular stimulation. When investigating PTM crosstalk, use sequential immunoprecipitation approaches where one modification is immunoprecipitated first, followed by analysis of other modifications on the same TCEANC2 population. To connect PTMs with functional outcomes, correlate modification patterns with TCEANC2 localization, protein-protein interactions, and transcriptional activity assays under various cellular conditions .

How can researchers use TCEANC2 antibodies in high-throughput screening applications?

TCEANC2 antibodies can be effectively integrated into high-throughput screening (HTS) platforms to investigate gene regulation networks and drug effects on transcriptional machinery. For cell-based high-content screening, establish stable cell lines expressing fluorescently-tagged TCEANC2 or use optimized immunofluorescence protocols with TCEANC2 antibodies to monitor subcellular localization changes in response to compound libraries or genetic perturbations . When developing automated ELISA-based screens, optimize plate coating with recombinant TCEANC2 protein (such as ABIN3074146) or capture antibodies against TCEANC2, then establish detection protocols using HRP or fluorescently-conjugated secondary antibodies that provide sufficient signal-to-noise ratios for automated plate readers . For reverse-phase protein array (RPPA) applications, validate TCEANC2 antibodies specifically for RPPA conditions, ensuring linear signal response across a range of protein concentrations and minimal cross-reactivity with other cellular proteins . When implementing multiplexed bead-based assays, conjugate TCEANC2 antibodies to distinctly coded beads and optimize detection parameters to enable simultaneous measurement of TCEANC2 alongside other proteins of interest in signaling pathways. For FACS-based screening approaches, establish protocols for intracellular staining of TCEANC2 with particular attention to permeabilization conditions that preserve nuclear epitopes . To ensure screening data quality, incorporate appropriate positive and negative controls in each plate, implement robust statistical analysis methods, and validate hits using orthogonal approaches such as Western blotting or qPCR .

What emerging techniques might enhance TCEANC2 antibody applications in research?

Several cutting-edge technologies have the potential to significantly advance TCEANC2 antibody applications in research. Proximity labeling methods such as BioID or APEX, when combined with TCEANC2 antibodies, could provide comprehensive mapping of the protein's interactome in native cellular contexts, revealing previously unknown associations with transcriptional machinery components . Super-resolution microscopy techniques including STORM, PALM, and STED can overcome the diffraction limit to visualize TCEANC2's precise nuclear distribution and co-localization with other transcription factors at nanometer-scale resolution, providing insights into functional nuclear domains . Live-cell imaging using single-domain antibody fragments (nanobodies) derived from conventional TCEANC2 antibodies could enable real-time visualization of TCEANC2 dynamics during transcriptional events without fixation artifacts. Mass cytometry (CyTOF) utilizing metal-conjugated TCEANC2 antibodies offers opportunities for highly multiplexed single-cell analysis of transcription factor networks across heterogeneous cell populations . Microfluidic antibody-based assays could enable analysis of TCEANC2 expression and modifications in limited samples such as patient biopsies or rare cell populations. CRISPR-based tagging of endogenous TCEANC2 combined with antibody detection provides ways to study the protein under physiological expression levels while facilitating pull-down experiments. Single-molecule pull-down (SiMPull) using TCEANC2 antibodies could reveal stoichiometry and composition of individual TCEANC2-containing complexes, providing insights into functional heterogeneity not detectable in bulk assays .

How might TCEANC2 antibodies contribute to understanding disease-associated transcriptional dysregulation?

TCEANC2 antibodies have significant potential to advance our understanding of transcriptional dysregulation in various disease states. In cancer research, TCEANC2 antibodies can be applied to tissue microarrays spanning multiple tumor types to establish expression patterns and correlations with clinical outcomes, potentially identifying cancer subtypes where TCEANC2 drives pathogenesis . For neurodegenerative disorders, which often involve aberrant transcriptional regulation, immunohistochemistry with TCEANC2 antibodies in brain tissue sections can reveal altered expression or localization patterns associated with disease progression . In the study of developmental disorders linked to chromosome 1 abnormalities, where TCEANC2 is located, antibody-based approaches can help determine if TCEANC2 dysregulation contributes to pathological phenotypes . For inflammatory diseases characterized by altered gene expression programs, single-cell analysis with TCEANC2 antibodies can identify specific immune cell populations with dysregulated transcriptional control. In the investigation of cardiac pathologies, particularly those affecting development where transcriptional regulation is crucial, TCEANC2 antibodies can help map expression patterns throughout heart development and disease states . For rare genetic disorders potentially involving TCEANC2, patient-derived cell models analyzed with specific antibodies can reveal altered protein function, localization, or interaction networks. In therapeutic development, TCEANC2 antibodies can be utilized in high-content screening assays to identify compounds that normalize aberrant TCEANC2 expression or function in disease models, potentially leading to novel therapeutic approaches targeting transcriptional regulators .